ProfileGDS5678 / 1417527_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 42% 41% 61% 43% 40% 29% 41% 42% 42% 41% 42% 41% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9490340
GSM967853U87-EV human glioblastoma xenograft - Control 22.9597642
GSM967854U87-EV human glioblastoma xenograft - Control 32.9554941
GSM967855U87-EV human glioblastoma xenograft - Control 43.5819561
GSM967856U87-EV human glioblastoma xenograft - Control 52.9352643
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0194240
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6970429
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9432341
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9439842
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9536142
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9449641
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9476142
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9578441
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1703649